RH5.1-CyRPA-Ripr antigen combination vaccine shows little improvement over RH5.1 in a preclinical setting
<strong>Background: </strong>RH5 is the leading vaccine candidate for the Plasmodium falciparum blood stage and has shown impact on parasite growth in the blood in a human clinical trial. RH5 binds to Ripr and CyRPA at the apical end of the invasive merozoite form, and this complex, desi...
Những tác giả chính: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Định dạng: | Journal article |
Ngôn ngữ: | English |
Được phát hành: |
Frontiers Media
2022
|